{"id":"NCT01298323","sponsor":"Sanofi","briefTitle":"Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","officialTitle":"A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-25","primaryCompletion":"2013-04-26","completion":"2025-03-13","firstPosted":"2011-02-17","resultsPosted":"2014-11-24","lastUpdate":"2025-04-24"},"enrollment":205,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Locally Advanced or Metastatic Medullary Thyroid Cancer","Medullary Thyroid Cancer"],"interventions":[{"type":"BEHAVIORAL","name":"Patient outreach","otherNames":[]},{"type":"DRUG","name":"Vandetanib","otherNames":["SAR390530"]}],"arms":[{"label":"Vandetanib Control","type":"ACTIVE_COMPARATOR"},{"label":"Experimental","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib","primaryOutcome":{"measure":"Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach Program.","timeFrame":"12 months","effectByArm":[{"arm":"Vandetanib 300 mg+Outreach Program","deltaMin":51.65,"sd":35.548},{"arm":"Vandetanib 300 mg","deltaMin":45.19,"sd":36.347}],"pValues":[{"comp":"OG000 vs OG001","p":"0.199"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":66,"countries":["Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","Germany","Greece","India","Israel","Italy","Poland","Russia","South Korea","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1433&filename=D4200C00088_Study_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":103},"commonTop":["Diarrhoea","Hypertension","Rash","Nausea","Dermatitis acneiform"]}}